The Moncton Hospital

Summary

The Moncton Hospital is a medical facility located in MONCTON, New Brunswick. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Non-Small Cell Lung Cancer, Parkinson's disease and other specialties. The Moncton Hospital is involved with conducting 95 clinical trials across 122 conditions. There are 1 research doctors associated with this hospital, such as Maged M. Salem.

Top PIs

Clinical Trials running at The Moncton Hospital

Breast Cancer

Multiple Myeloma

Chronic Lymphocytic Leukemia

Lymphoma

Lung Cancer

Follicular Lymphoma

Small Cell Lymphoma

Chronic B-Cell Leukemia

Plasma Cell Neoplasm

Solid Tumors

Patritumab Deruxtecan

for Breast Cancer

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

Recruiting

2 awards

Phase 3

2 criteria

sac-TMT + Pembrolizumab

for Breast Cancer

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.

Recruiting

2 awards

Phase 3

5 criteria

Inavolisib + CDK4/6 Inhibitor + Letrozole

for Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

Recruiting

1 award

Phase 3

6 criteria